GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. Its drug candidates include Uproleselan, GMI-1687, GMI-1359, Galectin Antagonists and Rivipansel. Uproleselan is a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia and a hematologic cancer. As a life-cycle extension to uproleselan, it has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is designed to inhibit both E-selectin and CXCR4. The Galectin-3 is a carbohydrate-binding protein. Rivipansel is a glycomimetic drug that acts as a pan-selectin antagonist that binds to all three members of the selectin family, E-, P- and L-selectin, for the treatment of vaso-occlusive crisis.